Yingzi Cui
Overview
Explore the profile of Yingzi Cui including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
24
Citations
90
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Cui Y, Qi Y, Ding L, Ding S, Han Z, Wang Y, et al.
Trends Cell Biol
. 2023 Jul;
34(1):31-47.
PMID: 37419737
In mammals, miRNAs recognize target mRNAs via base pairing, which leads to a complex 'multiple-to-multiple' regulatory network. Previous studies have focused on the regulatory mechanisms and functions of individual miRNAs,...
12.
Xu Z, Liu Z, Wang Y, Xue J, Chang T, Cui Y, et al.
Expert Rev Clin Pharmacol
. 2023 Mar;
16(4):363-370.
PMID: 36883362
Background: Glucagon-like peptide-1 (GLP-1) is an endogenous incretin hormone. Liraglutide, a GLP-1 receptor agonist, can lower blood sugar by increasing insulin production and inhibiting the production of glucagon. This study...
13.
Wang Y, Xue J, Su Z, Cui Y, Liu G, Yang W, et al.
Expert Opin Investig Drugs
. 2023 Feb;
32(3):263-270.
PMID: 36757390
Background: Dasatinib (Sprycel®) is a tyrosine kinase inhibitor for treating chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia. Research Design & Methods: We designed a clinical study to demonstrate...
14.
Chang T, Cui Y, Zhang Y, Ma J, Tan J, Wang J
Evid Based Complement Alternat Med
. 2023 Feb;
2023:4612036.
PMID: 36733845
Background: Systematic reviews focusing on the effectiveness of different kinds of healthcare interventions have been widely published, but there were few guidelines for reporting safety concerns before 2016. The PRISMA...
15.
Xu P, Zhang Y, Chang T, Jiang L, Lv Z, Zhang Y, et al.
Medicine (Baltimore)
. 2022 Dec;
101(50):e31454.
PMID: 36550882
Background: Immunosuppressive drugs are routinely used to treat myasthenia gravis (MG). However, current recommendations provide limited evidence to support treatment options, leading to considerable variation in practice among healthcare specialists....
16.
Zhang Y, Chang T, Lu Q, Cui Y, Zhang D, Wang B, et al.
Evid Based Complement Alternat Med
. 2022 Oct;
2022:7416448.
PMID: 36225188
Myasthenia gravis (MG) is a rare and refractory autoimmune disease, and Qi Shen Di Huang (QSDH) drug formulary is an in-hospital herbal decoction with proven clinical efficacy in treating MG....
17.
Cui Y, Cui D, Ren X, Chen X, Liu G, Liu Z, et al.
Front Pharmacol
. 2022 May;
13:907413.
PMID: 35600852
[This corrects the article DOI: 10.3389/fphar.2021.660541.].
18.
Xu Z, Wang Y, Liu G, Chen J, Wang W, Cheng Y, et al.
Expert Opin Investig Drugs
. 2022 Apr;
31(7):737-746.
PMID: 35427205
Background: Lenvatinib is a tyrosine kinase receptor inhibitor that inhibits vascular and endothelial growth factor receptor kinase activity. This study evaluated the bioequivalence and safety of lenvatinib with Lenvima® ....
19.
Wang Q, Yang Q, Liu C, Wang G, Song H, Shang G, et al.
Proc Natl Acad Sci U S A
. 2022 Jan;
119(4).
PMID: 35046043
Receptor usage defines cell tropism and contributes to cell entry and infection. Coxsackievirus B (CVB) engages coxsackievirus and adenovirus receptor (CAR), and selectively utilizes the decay-accelerating factor (DAF; CD55) to...
20.
Liu G, Xu Z, Yang W, Xue J, Wang Y, Liu Z, et al.
Expert Opin Biol Ther
. 2021 Oct;
22(2):187-195.
PMID: 34607519
Background: Perjeta® is a recombinant, humanized monoclonal antibody that has been marketed and approved for the targeted therapy of human epidermal growth factor receptor (HER2) positive breast cancer in the...